ESMO26: GSK’s Mo-Rez seeks an edge in a crowded ADC field in ovarian cancer
GSK’s Mo-Rez is projected to reach global annual sales of $540m by 2032 based on GlobalData’s analyst consensus forecast.
GSK’s Mo-Rez is projected to reach global annual sales of $540m by 2032 based on GlobalData’s analyst consensus forecast.